Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mutanase** is an endo-acting enzyme that hydrolyzes α-1,3-glucosidic linkages in water-insoluble mutan, a glucan polymer produced by cariogenic streptococci such as *Streptococcus mutans*. By degrading the extracellular polysaccharide matrix of dental biofilms, it disrupts plaque formation, facilitates biofilm removal, and shows potential as an anticaries agent in oral care products like toothpastes, mouthwashes, and denture cleaners. Sources include bacteria like *Paracoccus mutanolyticus*, *Paenibacillus humicus*, and *Bacillus* species; it also exhibits antifungal activity against pathogens like *Colletotrichum capsici* and *Candida albicans* by targeting fungal cell wall α-1,3-glucans.[1][2][3][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mutanase.